Gerald L. Andriole, Jr., MD, presented “PET Imaging for Prostate Cancer” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.
How to cite: Andriole, Gerald L. “PET Imaging for Prostate Cancer” August 10th, 2020. Accessed Jul 2024. https://grandroundsinurology.com/pet-imaging-for-prostate-cancer/
Summary:
Gerald L. Andriole, Jr., MD, the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri, reviews the 2020 NCCN Guidelines, focusing on PET imaging for prostate cancer and related studies. He establishes that PET/CT and PET/MRI for detection of biochemically recurrent disease have been approved, though the majority of the data collected is specifically for the Ga-68 PSMA tracer. F-18 DCFBC, F-18DCFPyl, and F-18 PSMA 1007 are currently being evaluated for possible advantages over Ga-68 PSMA. Dr. Andriole then discusses several studies which demonstrate both the benefits and limitations of PET-directed therapies in the prostate cancer setting.Dr. Andriole concludes by looking at studies which compared PSMA PET to conventional imaging and found PSMA PET to be significantly more effective.
For more on imaging for prostate cancer, visit our learning center.
About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Andriole presented this lecture during this year’s virtual conference in August 2020.
ABOUT THE AUTHOR
Gerald L. Andriole, Jr., MD, is the global Chief Medical Officer at Prostatype Genomics. He previously was Professor and Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University. He also formerly served as the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed his Urology Residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a Fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 40 years of consistent contributions in the areas of prostate cancer screening and prevention research as well as BPH. He has contributed over 450 peer-reviewed publications. He chaired the Prostate Committee of NCI’s PLCO Cancer Screening Trial, the Steering Committee of the international REDUCE Chemoprevention Trial and the Prostate Committee of the SUO Clinical Trials Consortium. He is a member of the American Urological Association, the Academy of Master Surgical Educators of the American College of Surgeons, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.
He has received the Outstanding Achievement Award from the Urologic Oncology Branch of NCI, the Distinguished Clinician Award from Washington University, the Alumni Award from Jefferson Medical College and the Williams Award for Prostate Cancer Research Excellence from the AUA Urology Care Foundation, among others.
